Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5969.39 | 1445 / 1445 | 100% | 40.77 | 183 / 183 |
prostate | 100% | 8397.60 | 245 / 245 | 100% | 31.18 | 502 / 502 |
thymus | 100% | 7296.73 | 653 / 653 | 100% | 35.09 | 605 / 605 |
breast | 100% | 7281.85 | 459 / 459 | 100% | 28.12 | 1116 / 1118 |
kidney | 100% | 5373.58 | 89 / 89 | 100% | 32.85 | 897 / 901 |
intestine | 100% | 6606.35 | 966 / 966 | 99% | 27.28 | 522 / 527 |
bladder | 100% | 6675.90 | 21 / 21 | 99% | 21.24 | 499 / 504 |
stomach | 100% | 4780.04 | 359 / 359 | 99% | 28.91 | 283 / 286 |
uterus | 100% | 8021.76 | 170 / 170 | 99% | 21.29 | 453 / 459 |
skin | 100% | 6065.52 | 1807 / 1809 | 99% | 25.08 | 465 / 472 |
pancreas | 98% | 3029.78 | 322 / 328 | 100% | 28.27 | 178 / 178 |
ovary | 100% | 9201.98 | 180 / 180 | 98% | 26.92 | 422 / 430 |
lung | 100% | 9379.75 | 578 / 578 | 98% | 26.94 | 1131 / 1155 |
adrenal gland | 100% | 5876.07 | 258 / 258 | 97% | 18.25 | 222 / 230 |
liver | 100% | 3003.17 | 226 / 226 | 95% | 14.13 | 385 / 406 |
brain | 77% | 1751.37 | 2026 / 2642 | 97% | 20.25 | 681 / 705 |
adipose | 100% | 7081.28 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7002.24 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 25.12 | 29 / 29 |
spleen | 100% | 9458.90 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 28.29 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.23 | 1 / 1 |
heart | 99% | 3187.76 | 853 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 14.20 | 77 / 80 |
peripheral blood | 94% | 5551.11 | 872 / 929 | 0% | 0 | 0 / 0 |
muscle | 86% | 2045.80 | 694 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0051607 | Biological process | defense response to virus |
GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
GO_0032728 | Biological process | positive regulation of interferon-beta production |
GO_0006513 | Biological process | protein monoubiquitination |
GO_0045089 | Biological process | positive regulation of innate immune response |
GO_0060340 | Biological process | positive regulation of type I interferon-mediated signaling pathway |
GO_0032479 | Biological process | regulation of type I interferon production |
GO_0034340 | Biological process | response to type I interferon |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_0045087 | Biological process | innate immune response |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | TRIM56 |
Protein name | E3 ubiquitin-protein ligase TRIM56 (EC 2.3.2.27) (RING finger protein 109) (Tripartite motif-containing protein 56) Tripartite motif containing 56 |
Synonyms | RNF109 |
Description | FUNCTION: E3 ubiquitin-protein ligase that plays a key role in innate antiviral immunity by mediating ubiquitination of CGAS and STING1 . In response to pathogen- and host-derived double-stranded DNA (dsDNA), targets STING1 to 'Lys-63'-linked ubiquitination, thereby promoting its homodimerization, a step required for the production of type I interferon IFN-beta (By similarity). Also mediate monoubiquitination of CGAS, thereby promoting CGAS oligomerization and subsequent activation . Promotes also TNFalpha-induced NF-kappa-B signaling by mediating 'Lys-63'-linked ubiquitination TAK1, leading to enhanced interaction between TAK1 and CHUK/IKKalpha . Independently of its E3 ubiquitin ligase activity, positive regulator of TLR3 signaling. Potentiates extracellular double stranded RNA (dsRNA)-induced expression of IFNB1 and interferon-stimulated genes ISG15, IFIT1/ISG56, CXCL10, OASL and CCL5/RANTES . Promotes establishment of an antiviral state by TLR3 ligand and TLR3-mediated chemokine induction following infection by hepatitis C virus . Acts as a restriction factor of Zika virus through direct interaction with the viral RNA via its C-terminal region . . |
Accessions | ENST00000306085.11 [Q9BRZ2-1] C9JI91 ENST00000467847.1 Q9BRZ2 ENST00000412507.1 A0A0D9SF19 |